Publications

Bicalutamide ('Casodex') 150 Mg in Addition to Standard Care in Patients with Nonmetastatic Prostate Cancer: Updated Results from a Randomised Double-Blind Phase Iii Study (Median Follow-Up 5.1 Y) in the Early Prostate Cancer Programme

AuthID
P-000-37F

Author(s)

Wirth, M

Tyrrell, C

Delaere, K

Sanchez Chapado, M

Ramon, J

Wallace, DMA

Hetherington, J

Pina, F

Heyns, C

Borchers, T

Morris, T

Armstrong, J

Group Author(s)

Casodex Early Prostate Canc Trialists

Document Type

Article

Year published

2005

Published

in PROSTATE CANCER AND PROSTATIC DISEASES, ISSN: 1365-7852

Volume: 8, Issue: 2, Pages: 194-200 (7)

Indexing

Wos^®

Scopus^®

Crossref^®

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1038/sj.pcan.4500799

Pubmed: 15931272

Scopus: 2-s2.0-23944447196

Wos: WOS:000230755700025

Source Identifiers

ISSN: 1365-7852

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Bicalutamide ('Casodex') 150 Mg in Addition to Standard Care in Patients with Nonmetastatic Prostate Cancer: Updated Results from a Randomised Double-Blind Phase Iii Study (Median Follow-Up 5.1 Y) in the Early Prostate Cancer Programme

Useful Links

Get Help

Federated Authentication (Click on the image)

Bicalutamide ('Casodex') 150 Mg in Addition to Standard Care in Patients with Nonmetastatic Prostate Cancer: Updated Results from a Randomised Double-Blind Phase Iii Study (Median Follow-Up 5.1 Y) in the Early Prostate Cancer Programme

Useful Links

Get Help